Dr. Argilés on BRAF-Mutations in Colorectal Cancer

Guillem Argiles, MD
Published: Friday, Jul 10, 2015




Guillem Argilés, MD, department of Medical Oncology, Vall d’Hebron University Hospital, discusses the benefits of molecular subtyping in colorectal cancer.

Identifying new subtypes in colorectal cancer has made a significant impact on treatment options for colorectal cancer, Argilés says.

By identifying and targeting BRAF-mutations, patients with a previously poor prognosis are experiencing improved survival outcomes and response rates.

Additional subtyping and targeted therapies for those molecular subtypes is key to combating colorectal cancer, says Argilés.
 



Guillem Argilés, MD, department of Medical Oncology, Vall d’Hebron University Hospital, discusses the benefits of molecular subtyping in colorectal cancer.

Identifying new subtypes in colorectal cancer has made a significant impact on treatment options for colorectal cancer, Argilés says.

By identifying and targeting BRAF-mutations, patients with a previously poor prognosis are experiencing improved survival outcomes and response rates.

Additional subtyping and targeted therapies for those molecular subtypes is key to combating colorectal cancer, says Argilés.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x